RIGEL PHARMACEUTICALS INC

The company is a biotechnology business that develops and provides small-molecule therapies for patients with hematologic disorders and cancer. Its commercial portfolio features three approved drugs: fostamatinib, an oral kinase inhibitor for adults with chronic immune thrombocytopenia; olutasidenib, a targeted therapy for relapsed or refractory acute myeloid leukemia; and pralsetinib, a kinase inhibitor for metastatic non-small cell lung cancer and advanced thyroid cancer. Its primary end customers are hematology and oncology patients, reached via wholesale distributors, specialty pharmacies, and healthcare providers.

The provided text does not state the company's headquarters. Geographically, the company directly commercializes its therapies within the United States and expands internationally via commercial partnerships. Its products are approved or commercially available in various countries, including Canada, Israel, Japan, South Korea, the United Kingdom, and European Union nations such as France, Germany, Italy, and Spain. Licensing and regulatory efforts also cover Latin America and additional global territories.

Summary of the business section of Rigel Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025 , we have 172 full-time and 2 part-time employees. Of these employees, 85 were engaged in commercial activities, 52 were engaged in development activities, and 37 were e”